Search the Newsreel

Acumen's Q2 Loss Narrows; Topline Phase 2 Data For Alzheimer's Drug Sabirnetug In Late '26

(RTTNews) - Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company, on Wednesday announced second quarter financial results and noted a lower net loss owing to reduced research and development (R&D) expenses. The company is engaged in developing novel therapeutics targeting toxic soluble amyloid beta …

Natco Pharma Shares End 5% Lower As Q1 Results Spooks Investors; Dividend Declared

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Posts Strong Interim Profit Rebound Despite Revenue Dip

Alebund Pharmaceuticals Wins Shareholder Backing for Auditor Change and New Capital Mandates

Tianjin Da Ren Tang Proposes Governance-Focused Amendments to Articles of Association

Tianjin Da Ren Tang Board Clears FY2026 Half-Year Reports and Governance Changes

Tianjin Pharmaceutical Da Ren Tang Updates Risk Review of Group Finance Unit

Tianjin Da Ren Tang Redirects Placement Proceeds to Working Capital After Project Cessations

Here's Why We're A Bit Worried About aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation

Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion

Irish biopharmaceutical company Jazz Pharmaceuticals plc has announced its acquisition of American Actio Biosciences, Inc. for $1.32 billion. The deal involves an upfront payment of $820 million and an additional $500 million contingent on drug approval and sales milestones. Jazz will gain control of …

Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 96.7% in the second quarter, selling 309,427 shares and retaining 10,573 shares valued at $2.55 million. Despite this, institutional investors and hedge funds collectively own 89.14% of the company, and …

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals(NASDAQ: IONS) …

TAK|Takeda Pharmaceutical Co Ltd|Price:17.395|Chg%:-0.235

TAK|Takeda Pharmaceutical Co Ltd|Price:17.405|Chg%:-0.005

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

COLLEGIUM PHARMACEUTICAL INC : NEEDHAM CUTS TARGET PRICE TO $46 FROM $56

Needham has revised its target price for Collegium Pharmaceutical Inc (NASDAQ: COLL) downwards from $56 to $46. This article, published on August 7th, highlights the analyst's updated outlook on the pharmaceutical company.

Innate Pharma prices €30M share offering to fund lead cancer drug

Innate Pharma has priced a €30 million share offering to fund the clinical development of its lead cancer drug candidate, IPH4502, and its preclinical antibody-drug conjugate portfolio. The French biotech issued 17,647,059 new ordinary shares at €1.70 each, expecting net proceeds of €27.6 million. …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

Pomerantz LLP is investigating potential securities fraud claims against Immix Biopharma, Inc. (IMMX) following a significant drop in its stock price. The investigation stems from the company's termination of its Chief Medical Officer, Richard Graydon, who was later identified by media outlets as Ronald …

Citizens reiterates Immix Biopharma stock rating on pipeline progress

Citizens reiterated a "Market Outperform" rating and a $23.00 price target for Immix Biopharma (NASDAQ:IMMX), citing strong pipeline progress and potential for significant upside despite recent financial losses and an "overvalued" assessment by InvestingPro. The firm highlighted upcoming top-line results for NXC-201 in September …

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research

Zacks Research has upgraded Inovio Pharmaceuticals (NASDAQ:INO) to a "strong-buy" rating. This upgrade comes as the company reported a quarterly loss of $0.07 per share, beating analyst expectations, and anticipates an FDA decision for its key product INO-3107 by October 30, 2026. The company …

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend

Sihuan Pharmaceutical Sets Board Meeting to Approve Interim Results and Dividend Plan

Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views

Analysts have raised their fair value estimate for Fennec Pharmaceuticals (FENC) from US$15.33 to US$17.67 per share, attributing this increase to stronger-than-expected PEDMARK revenue, its expanded use across various tumor types, and improved operating leverage. Several firms, including B. Riley, Wedbush, and H.C. Wainwright, …

Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership

Balyasny Asset Management L.P. and its affiliated entities have reported a 6.03% beneficial ownership stake in Crescent Biopharma, Inc., totaling 1,662,917 shares of Class A common stock. This ownership is primarily held through Atlas Private Holdings (Cayman) Ltd. and Atlas Diversified Master Fund, Ltd. …

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

Four Innate Pharma executives set to appear in Aug. 14 webcast

Zhongzhi Pharmaceutical Sets Board Meeting to Review Interim Results and Possible Dividend

Island Pharmaceuticals Ltd Revenue Breakdown – ASX:ILA

Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance

Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting adjusted EBITDA margin above 35%. Chief executive officer Sean Brynjelsen said the …

Pharmaniaga 2Q Net Profit Surges 200%, Secures RM281.7M Insulin Contract

Dawnrays Pharmaceutical Sets Board Meeting to Approve Interim Results and Mull Dividend

Shenzhen Hepalink Sets Board Meeting to Review Interim Results and Dividend

Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System

The California State Teachers Retirement System significantly increased its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 2,158.3% in the first quarter, now holding 105,101 shares. Several other institutional investors also adjusted their positions in the company. Despite missing earnings per share estimates, Eyepoint Pharmaceuticals exceeded …

Lincoln Pharma Q1 Results FY27: PAT Rs 36 Cr, Revenue Rs 177 crore

Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test

Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, leading to significant share price pressure. Despite a "most popular narrative" suggesting the stock is 47.8% undervalued with a fair value of …